Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab: mechanisms and applications.

Literature DB >> 11742477

Rituximab: mechanisms and applications.

P W Johnson¹, M J Glennie.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2001 PMID： 11742477 PMCID： PMC2363990 DOI： 10.1054/bjoc.2001.2127

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

× No keyword cloud information.

46 in total

1. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study.

Authors: P W Johnson; K Swinbank; S MacLennan; D Colomer; B Debuire; T Diss; J Gabert; R K Gupta; A Haynes; M Kneba; M S Lee; E Macintyre; E Mensink; M Moos; G J Morgan; A Neri; A Johnson; G Reato; G Salles; M B van't Veer; J L Zehnder; E Zucca; P J Selby; F E Cotter
Journal: Ann Oncol Date: 1999-11 Impact factor: 32.976

2. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

Authors: J M Foran; D Cunningham; B Coiffier; P Solal-Celigny; F Reyes; M Ghielmini; P W Johnson; C Gisselbrecht; M Bradburn; J Matthews; T A Lister
Journal: Ann Oncol Date: 2000 Impact factor: 32.976

3. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.

Authors: N Milpied; B Vasseur; N Parquet; J L Garnier; C Antoine; P Quartier; A S Carret; D Bouscary; A Faye; B Bourbigot; Y Reguerre; A M Stoppa; P Bourquard; B Hurault de Ligny; F Dubief; A Mathieu-Boue; V Leblond
Journal: Ann Oncol Date: 2000 Impact factor: 32.976

4. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors: R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal: Nat Med Date: 2000-04 Impact factor: 53.440

5. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

Authors: J D Hainsworth; H A Burris; L H Morrissey; S Litchy; D C Scullin; J D Bearden; P Richards; F A Greco
Journal: Blood Date: 2000-05-15 Impact factor: 22.113

Review 6. Signaling antibodies in cancer therapy.

Authors: M S Cragg; R R French; M J Glennie
Journal: Curr Opin Immunol Date: 1999-10 Impact factor: 7.486

7. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.

Authors: I Kuehnle; M H Huls; Z Liu; M Semmelmann; R A Krance; M K Brenner; C M Rooney; H E Heslop
Journal: Blood Date: 2000-02-15 Impact factor: 22.113

8. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.

Authors: J M Foran; R K Gupta; D Cunningham; R A Popescu; A H Goldstone; J W Sweetenham; R Pettengell; P W Johnson; E Bessell; B Hancock; K Summers; J Hughes; A Z Rohatiner; T A Lister
Journal: Br J Haematol Date: 2000-04 Impact factor: 6.998

9. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors: J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal: Blood Date: 2000-06-15 Impact factor: 22.113

10. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.

Authors: A Harjunpää; S Junnikkala; S Meri
Journal: Scand J Immunol Date: 2000-06 Impact factor: 3.487

19 in total

Review 10. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies.

Authors: G Malviya; F Conti; M Chianelli; F Scopinaro; R A Dierckx; A Signore
Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-24 Impact factor: 9.236

Rituximab: mechanisms and applications.

1. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study.

2. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

3. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.

4. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

5. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

Review 6. Signaling antibodies in cancer therapy.

7. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.

8. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.

9. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

10. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.

1. Rituximab: a review of dermatological applications.

2. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.

3. Treatment of IgM antibody associated polyneuropathies using rituximab.

Review 4. Anti-CD20 monoclonal antibodies: historical and future perspectives.

5. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

6. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.

7. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.

Review 8. Targeting B cells for the treatment of rheumatoid arthritis.

Review 9. Rituximab: beyond simple B cell depletion.

Review 10. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies.